Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib

Am J Hematol. 2021 May 1;96(5):E137-E140. doi: 10.1002/ajh.26109. Epub 2021 Feb 11.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Benzamides / adverse effects
  • Benzamides / therapeutic use*
  • Combined Modality Therapy
  • Disease Progression
  • Drug Substitution
  • Follow-Up Studies
  • Humans
  • Immunotherapy, Adoptive
  • Kaplan-Meier Estimate
  • Lymphoma, Mantle-Cell / drug therapy*
  • Lymphoma, Mantle-Cell / genetics
  • Lymphoma, Mantle-Cell / therapy
  • Mutation
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrazines / adverse effects
  • Pyrazines / therapeutic use*
  • Recurrence
  • Salvage Therapy
  • Sample Size
  • Treatment Outcome
  • Whole Exome Sequencing
  • Withholding Treatment

Substances

  • Antineoplastic Agents
  • Benzamides
  • Protein Kinase Inhibitors
  • Pyrazines
  • acalabrutinib